Cargando…
Brain Metastases Status and Immunotherapy Efficacy in Advanced Lung Cancer: A Systematic Review and Meta-Analysis
BACKGROUND: Brain metastases (BMs) indicate poor outcomes and are commonly excluded in immunotherapy clinical trials in advanced lung cancer; moreover, the effect of BM status on immunotherapy efficacy is inconsistent and inconclusive. Therefore, we conducted a meta-analysis to assess the influence...
Autores principales: | Hu, Hao, Xu, Zhi-Yong, Zhu, Qian, Liu, Xi, Jiang, Si-Cong, Zheng, Ji-Hua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316922/ https://www.ncbi.nlm.nih.gov/pubmed/34335570 http://dx.doi.org/10.3389/fimmu.2021.669398 |
Ejemplares similares
-
Efficacy and safety of concomitant immunotherapy and denosumab in patients with advanced non-small cell lung cancer carrying bone metastases: A retrospective chart review
por: Li, Hong-Shuai, et al.
Publicado: (2022) -
The Long-Term and Short-Term Efficacy of Immunotherapy in Non-Small Cell Lung Cancer Patients With Brain Metastases: A Systematic Review and Meta-Analysis
por: Chu, Xianjing, et al.
Publicado: (2022) -
Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases
por: Lauko, Adam, et al.
Publicado: (2021) -
THER-09. IMPACT OF KRAS MUTATION STATUS ON THE EFFICACY OF IMMUNOTHERAPY IN LUNG CANCER BRAIN METASTASES
por: Lauko, Adam, et al.
Publicado: (2019) -
Author Correction: Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases
por: Lauko, Adam, et al.
Publicado: (2022)